Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts.

Aura Biosciences Inc.

The latest announcement is out from Auranova Resources Inc ( ($TSE:AURA) ). Auranova Resources Inc., a Canadian mineral exploration company targeti...

Auranova Raises $1.5 Million in Flow-Through Share Financing for Ontario Gold Exploration

The latest update is out from Auranova Resources Inc ( ($TSE:AURA) ). Auranova Resources has begun Phase 3 diamond drilling at its South Uchi Proje...

Auranova Launches Phase 3 Drilling and $1.5 Million Financing at South Uchi Gold Project

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aura Biosciences Inc (AURA) and Kezar Life Science...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Aura Biosciences Inc (AURA) and Kezar Life Sciences (KZR)

Auranova Resources Inc ( ($TSE:AURA) ) has shared an announcement. Auranova Resources has approved a Phase 3 diamond drill program for the South Uc...

Market Cap	$339.80M	P/E Ratio	N/A
52W High	$7.48	52W Low	$4.35
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	76.6%
Overall Score	75	Value Score	60
Quality Score	--	Technical Score	90

EPS Current Est	$-1.63	EPS Next Est	$-1.63
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AURA	$6.75	+1.73%	238.96K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AURA	$6.75	+1.7%	238.96K
3
4
5
6

AURA

AURA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Aura Biosciences Inc. Data in Excel

Get Aura Biosciences Inc. Data in Excel